Trial Profile
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Nov 2022
Price :
$35
*
At a glance
- Drugs Retifanlimab (Primary)
- Indications Anal cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms POD1UM-202
- Sponsors Incyte Corporation
- 11 Jan 2022 Status changed from active, no longer recruiting to completed.
- 20 Dec 2021 This trial has been completed in Denmark and Italy, according to European Clinical Trials Database record.
- 16 Dec 2021 This trial has been completed in Belgium, according to European Clinical Trials Database record.